An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate tolerability of darunavir (PREZISTA) or etravirine
(INTELENCE) in patients infected with human immunodeficiency virus type 1 (HIV-1) who are
naïve to these medications and in patients who have experienced tolerability issues on their
current or prior combination antiretroviral therapy (cART). The tolerability is evaluated by
switching the patients from their previous or current combination antiretroviral therapy
(cART) to either darunavir or etravirine.